BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Hemophilia Alliance - ECPv6.3.7//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://hemoalliance.org
X-WR-CALDESC:Events for Hemophilia Alliance
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231024T140000
DTEND;TZID=America/New_York:20231024T150000
DTSTAMP:20260826T221015
CREATED:20231003T184948Z
LAST-MODIFIED:20231005T175043Z
UID:45701-1698156000-1698159600@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Clinical Overview and Update from Sanofi for Efanesoctocog Alfa\, A High Sustained Factor VIII Therapy
DESCRIPTION:Date: Tuesday\, October 24\, 2023\nTime: 2:00pm – 3:00pm ET \n\n \nTITLE:\nA Clinical Overview and Update from Sanofi for Efanesoctocog Alfa\, A High Sustained Factor VIII Therapy \nOBJECTIVES: \n\nHighlighting both Efanesoctocog Alfa’s pediatric study\, the XTEND-Kids data that were presented at ISTH 2023\, as well as an observational study of patients who switched from current therapy to Efanesoctocog Alfa prophylaxis.\nHighlighting available lab monitoring program available to your centers.\n\nTARGET AUDIENCE:\nAll HTC Staff \nSPEAKER:\n\nNancy Epp\, PharmD\, BCACP \nNancy Epp is a Senior Medical Science Liaison with Sanofi. She supports the Sanofi hemophilia A and B portfolio to provide up-to-date scientific data to healthcare providers. Nancy is based in Houston\, Texas\, and can be reached by email at Nancy.Epp@sanofi.com.
URL:https://hemoalliance.org/alliance-events/a-clinical-overview-and-update-from-sanofi-for-efanesoctocog-alfa-a-high-sustained-factor-viii-therapy/
CATEGORIES:Members Only,Webinar
END:VEVENT
END:VCALENDAR